Analysis of the value of transvaginal color Doppler ultrasound parameters combined with systemic immune-inflammation index in predicting the risk of lymph node metastasis in cervical cancer

Background: The study aimed to explore the predictive value of transvaginal color Doppler ultrasound parameters combined with the systemic immune-inflammation index (SII) in assessing the risk of lymph node metastasis in cervical cancer. Methods: A total of 172 patients diagnosed with cervical cancer from January 2016 to January 2024 were enrolled, and divided into a lymph node metastasis group (56 cases) and a non-lymph node metastasis group (116 cases) based on biopsy results as the gold standard. Clinical data, transvaginal color Doppler ultrasound parameters, and SII were compared between the two groups. Variables showing significantly different values were selected to construct a logistic model, and the diagnostic performance was analyzed using the receiver operating characteristic (ROC) curve. Results: Logistic regression analysis identified Lymph Node Short-axis Diameter (SAD), tumor length-to-short-axis diameter ratio (LS) <2, peak systolic velocity (PSV), and SII as the independent risk factors for lymph node metastasis in cervical cancer patients. The transvaginal ultrasound pulsatility index (PI) and resistance index (RI) were protective factors. The predictive model incorporating SAD, LS, PSV, PI, RI, and SII achieved an area under the ROC curve (AUC) of 0.946, with a Youden index of 0.762, and sensitivity and specificity of 85.70% and 95.00%, respectively. Conclusions: The risk prediction model integrating transvaginal color Doppler ultrasound parameters and SII demonstrates high predictive value for cervical cancer lymph node metastasis, suggesting a valuable clinical application potential.

Transvaginal color Doppler ultrasound; Systemic immune-inflammation index; Cervical cancer; Lymph node metastasis; Risk prediction

[1] Ikeda M, Shida M, Shigeta S, Nagase S, Takahashi F, Yamagami W, et al. The trend and outcome of postsurgical therapy for high-risk early-stage cervical cancer with lymph node metastasis in Japan: a report from the Japan Society of Gynecologic Oncology (JSGO) guidelines evaluation committee. Journal of Gynecologic Oncology. 2021; 32: e44.

[2] Tewari KS. Cervical cancer. The New England Journal of Medicine. 2025; 392: 56–71.

[3] Perkins RB, Wentzensen N, Guido RS, Schiffman M. Cervical cancer screening: a review. JAMA. 2023; 330: 547–558.

[4] Nicolai L, Yigit R, Bleeker MCG, Bart J, van der Velden J, Mom CH. The risk of lymph node metastasis in the new FIGO 2018 stage IA cervical cancer with >7 mm diameter. Journal of Gynecologic Oncology. 2023; 34: e75.

[5] Cao L, Kong W, Li J, Song D, Jin B, Liu T, et al. Analysis of lymph node metastasis and risk factors in 975 patients with FIGO 2009 stage IA–IIA cervical cancer. Gynecologic and Obstetric Investigation. 2023; 88: 30–36.

[6] Yang XL, Wang MM, Kou LN, Lai H, Wu DJ. Conditional survival for high-risk early-stage cervical cancer patients with lymph node metastasis after hysterectomy. Current Problems in Cancer. 2021; 45: 100756.

[7] Peng Y, Liu J, Xie J, Li Q. Diagnostic value and efficacy evaluation value of transvaginal color doppler ultrasound parameters for uterine scar pregnancy and sub-type after cesarean section. BMC Medical Imaging. 2024; 24: 239.

[8] Guo S, Liu L, Li Y, Shi H, Cong AN. Correlation between nm23-H_1 expression and transvaginal color Doppler ultrasound performance after radiotherapy for cervical cancer. Translational Cancer Research. 2022; 11: 1354–1361.

[9] Liu P, Jiang Y, Zheng X, Pan B, Xiang H, Zheng M. Pretreatment systemic immune-inflammation index can predict response to neoadjuvant chemotherapy in cervical cancer at stages IB2–IIB. Pathology and Oncology Research. 2022; 28: 1610294.

[10] Shao X, Bai L, Liang J, Li M. Diagnostic value and clinical significance of serum miR-4534 combined with transvaginal color Doppler ultrasound in cervical cancer. Discover Oncology. 2024; 15: 403.

[11] Meng L, Yang Y, Hu X, Zhang R, Li X. Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis. Journal of Translational Medicine. 2023; 21: 79.

[12] Morrison J, Balega J, Buckley L, Clamp A, Crosbie E, Drew Y, et al. British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: recommendations for practice. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2022; 270: 50–89.

[13] Verit FF, Bese T, Demirkiran F. Correspondence on: the risk of lymph node metastasis in the new FIGO 2018 stage IA cervical cancer with >7 mm diameter by Nicolai et al. Journal of Gynecologic Oncology. 2024; 35: e91.

[14] Guani B, Mahiou K, Crestani A, Cibula D, Buda A, Gaillard T, et al. Clinical impact of low-volume lymph node metastases in early-stage cervical cancer: a comprehensive meta-analysis. Gynecologic Oncology. 2022; 164: 446–454.

[15] Olthof EP, van der Aa MA, Adam JA, Stalpers LJA, Wenzel HHB, van der Velden J, et al. The role of lymph nodes in cervical cancer: incidence and identification of lymph node metastases—a literature review. International Journal of Clinical Oncology. 2021; 26: 1600–1610.

[16] Yang S, Liu C, Li C, Hua K. Nomogram predicting lymph node metastasis in the early-stage cervical cancer. Frontiers in Medicine. 2022; 9: 866283.

[17] Xu M, Xie X, Cai L, Xie Y, Gao Q, Sun P. Risk factor assessment of lymph node metastasis in patients with FIGO stage IB1 cervical cancer. Frontiers in Oncology. 2022; 12: 809159.

[18] He H, He M, Zhou Q, Tang Y, Wang J, Li X, et al. Genetic analysis of cervical cancer with lymph node metastasis. Journal of Gynecologic Oncology. 2024; 35: e102.

[19] Wenzel HHB, Schnack TH, Van der Aa MA, Jensen PT, Høgdall CK, Hardie AN, et al. Risk factors for lymph node metastasis in women with FIGO 2018 IA cervical cancer with a horizontal spread of >7 mm. European Journal of Cancer. 2024; 212: 115063.

[20] Liu X, Xiao W, Qiao J, Luo Q, Gao X, He F, et al. Prediction of lymph node metastasis in endometrial cancer based on color Doppler ultrasound radiomics. Academic Radiology. 2024; 31: 4499–4508.

[21] Xu M, Xie X, Cai L, Liu D, Sun P. Preoperative scoring system for the prediction of risk of lymph node metastasis in cervical cancer. Scientific Reports. 2024; 14: 23860.

[22] Borges AC, Veloso H, Galindo P, Danés A, Chacon E, Mínguez JA, et al. Role of ultrasound in detection of lymph-nodes metastasis in gynecological cancers: systematic review and meta-analysis. Ultrasound in Obstetrics & Gynecology. 2024; 64: 155–163.

[23] Wang Y, Yang J, Wang Y. Serum miRNA combined with transvaginal color Doppler ultrasound diagnosis clinical research on cervical cancer. Journal of Ultrasound in Medicine. 2024; 43: 791–798.

[24] Kou J, Huang J, Li J, Wu Z, Ni L. Systemic immune-inflammation index predicts prognosis and responsiveness to immunotherapy in cancer patients: a systematic review and meta-analysis. Clinical and Experimental Medicine. 2023; 23: 3895–3905.

[25] Atasever Akkas E, Erdis E, Yucel B. Prognostic value of the systemic immune-inflammation index, systemic inflammation response index, and prognostic nutritional index in head and neck cancer. European Archives of Oto-Rhino-Laryngology. 2023; 280: 3821–3830.

[26] Wang HB, Xu XT, Tian MX, Ding CC, Tang J, Qian Y, et al. Prognostic values of the prognostic nutritional index, geriatric nutritional risk index, and systemic inflammatory indexes in patients with stage IIB–III cervical cancer receiving radiotherapy. Frontiers in Nutrition. 2023; 10: 1000326.

[27] Zhu Y, Shen B, Pei X, Liu H, Li G. CT, MRI, and PET imaging features in cervical cancer staging and lymph node metastasis. American Journal of Translational Research. 2021; 13: 10536.

[28] Ran C, Sun J, Qu Y, Long N. Clinical value of MRI, serum SCCA, and CA125 levels in the diagnosis of lymph node metastasis and para-uterine infiltration in cervical cancer. World Journal of Surgical Oncology. 2021; 19: 343.

[29] Sun X, Wei Z, Luo Y, Wang M. Exploration of the evaluation value of combined magnetic resonance imaging and ultrasound blood flow parameters in cervical lymph node metastasis of thyroid cancer. Cancer Management and Research. 2025; 17: 651–659.

[30] Zhao J, Cai J, Wang H, Dong W, Zhang Y, Wang S, et al. Region-specific risk factors for pelvic lymph node metastasis in patients with stage IB1 cervical cancer. Journal of Cancer. 2021; 12: 2624–2632.

[31] Zhang H, Lin J, Huang Y, Chen Y. The systemic immune-inflammation index as an independent predictor of survival in patients with locally advanced esophageal squamous cell Carcinoma Undergoing Neoadjuvant Radiotherapy. Journal of Inflammation Research. 2024; 17: 4575–4786.

[32] Guo J, Lv W, Wang Z, Shang Y, Yang F, Zhang X, et al. Prognostic value of inflammatory and nutritional markers for patients with early-stage poorly-to moderately-differentiated cervical squamous cell carcinoma. Cancer Control. 2023; 30: 10732748221148913.